IFIH1 and interstitial lung disease: Data on the presence or absence of interstitial lung disease in the cohort was incomplete and not included in regression analyses however, using the same cohort we have previously shown that 19% of those with anti-MDA5 developed interstitial lung disease and none rapidly progressive interstitial lung disease [3].